Middle East African journal of ophthalmology · 2009
Intravitreal bevacizumab (avastin) as an adjuvant treatment in cases of neovascular glaucoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghanem Asaad A, El-Kannishy Amr M, El-Wehidy Ahmed S, El-Agamy Amira F
Аннотация
PURPOSE: To evaluate the effect of intravitreal bevacizumab (avastin) injection in cases of neovascular glaucoma.
STUDY DESIGN: Clinical case series.
MATERIALS AND METHODS: Sixteen eyes of 16 patients with rubeosis iridis and secondary glaucoma were administered intravitreal injection of bevacizumab (2.5 mg). The patients were followed for 2 months.
RESULTS: We noted partial or complete regression of iris neovascularization 1 week after injection of bevacizumab. Reproliferation of new vessels was detected in 25% of the cases after 2 months. The mean intraocular pressure (IOP) before injection was 28+/- 9.3 mm Hg under topical ss-blocker and systemic acetazolamide. One week after injection, the IOP decreased to 21.7+/- 11.5 mm Hg (5 cases without anti-glaucoma drugs, 6 cases with topical ss-blocker and 5 cases with both topical ss-blocker and systemic acetazolamide).
CONCLUSION: Intravitreal bevacizumab (avastin) injection leads to regression of iris neovascularization with subsequent drop of IOP in eyes with neovascular glaucoma.
STUDY DESIGN: Clinical case series.
MATERIALS AND METHODS: Sixteen eyes of 16 patients with rubeosis iridis and secondary glaucoma were administered intravitreal injection of bevacizumab (2.5 mg). The patients were followed for 2 months.
RESULTS: We noted partial or complete regression of iris neovascularization 1 week after injection of bevacizumab. Reproliferation of new vessels was detected in 25% of the cases after 2 months. The mean intraocular pressure (IOP) before injection was 28+/- 9.3 mm Hg under topical ss-blocker and systemic acetazolamide. One week after injection, the IOP decreased to 21.7+/- 11.5 mm Hg (5 cases without anti-glaucoma drugs, 6 cases with topical ss-blocker and 5 cases with both topical ss-blocker and systemic acetazolamide).
CONCLUSION: Intravitreal bevacizumab (avastin) injection leads to regression of iris neovascularization with subsequent drop of IOP in eyes with neovascular glaucoma.